ReviewEULAR rheumatology open2026
CAR-T cells and CAR-Treg cells for treatment of inflammatory bowel diseases.
Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are therapeutically challenging chronic inflammatory diseases of the intestine. Despite major advances in biologic and small-molecule therapies, many patients with IBD experience primary nonresponse, secondary loss of response, or severe complications, underscoring the need for innovative therapeutic strategies that lead to sustained immune recalibration. Chimeric antigen receptor (CAR)-based cellular therapies represent an emerging new concept for transformative medicine. These CAR-T cells are engineered to recognise defined surface antigens, such as CD19, and are therefore ideally suited to eliminate selected pathogenic immune cell populations, such as B lymphocytes. In IBD, this concept has gained momentum through evidence implicating mucosal B cells, plasmablasts, and disease-associated humoral responses as potential disease drivers in UC. A recent case report suggested that CD19-directed CAR-T cell therapy may induce profound remission in multirefractory UC. In parallel, CAR regulatory T cells (CAR Tregs) may offer a complementary approach for IBD therapy by redirecting suppressive immune function in the inflamed intestine. Particularly, interleukin-23 receptor-targeted CAR Tregs provide a mechanistically attractive strategy to modulate T helper-type 17-driven mucosal inflammation in CD. Safety considerations and translational challenges are potential concerns with regard to CAR-T and CAR-Treg therapies in IBD. However, these technologies may enable precision immune engineering for selected refractory disease endotypes in IBD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.